NASDAQ · PNT
Healthcare · Biotechnology
$12.50
Up+$0.02 (+0.16%)
Updated Aug 22, 2026, 2:18 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PNT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PNT.
PNT research
Company profile and research snapshot.
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 21, 2023 | Brookline Capital | Hold | — |
| Oct 24, 2023 | Piper Sandler | Neutral | — |
| Oct 6, 2023 | Raymond James | Market Perform | — |
| Oct 4, 2023 | Truist Securities | Hold | — |
| Oct 4, 2023 | JonesTrading | Hold | — |
No generated briefing is available yet.
businesswire.com · Dec 10, 2025
TORTOLA, British Virgin Islands--(BUSINESS WIRE)---- $ARB #AI--Pheasant Network raised 2M USD led by mint with Ethereum Foundation support to advance AI Intent cross chain tech and expand $PNT and AI routing.
GlobeNewswire Inc. · Dec 18, 2023
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS)
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PNT.
No results
No recent SID articles mention PNT.
